Pacira Pharmaceuticals is collaborating with health care insurance company Aetna—with the support of the American Association of Oral and Maxillofacial Surgeons (AAOMS)—on a national program aimed at reducing the number of opioid tablets prescribed to patients undergoing impacted third molar (wisdom tooth) extractions by at least 50%.
Aetna will reimburse oral surgeons enrolled in the program for their use of Pacira’s nonopioid analgesic bupivacaine (Exparel) in impacted third